GenAssist Therapeutics
新芽基因
GenAssist Therapeutics
Biotech/Healthcare
New Bud Gene is China's first company dedicated to developing systemically administered gene therapies using base-editing technology. Base editing is a next-generation gene-editing technology that enables precise gene correction while significantly improving the safety and efficacy of gene editing.
Latest round: Series A (2023)
Source: ChinaBulls — chinabulls.com
Last updated 2023-01-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.